Next Article in Journal
Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis
Next Article in Special Issue
Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles
Previous Article in Journal
Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?
Previous Article in Special Issue
Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus
Review

Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles

1
Institute of Regenerative Medicine and Biotherapies, INSERM, University of Montpellier, 34090 Montpellier, France
2
Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Hôpital Lapeyronie, 34090 Montpellier, France
*
Author to whom correspondence should be addressed.
Academic Editors: Thomas Ritter, Matthew Griffin and Aideen Ryan
Int. J. Mol. Sci. 2017, 18(4), 889; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040889
Received: 31 March 2017 / Revised: 20 April 2017 / Accepted: 20 April 2017 / Published: 22 April 2017
Extracellular vesicles (EVs) are important mediators of cell-to-cell communication pathways via the transport of proteins, mRNA, miRNA and lipids. There are three main types of EVs, exosomes, microparticles and apoptotic bodies, which are classified according to their size and biogenesis. EVs are secreted by all cell types and their function reproduces that of the parental cell. They are involved in many biological processes that regulate tissue homeostasis and physiopathology of diseases. In rheumatic diseases, namely osteoarthritis (OA) and rheumatoid arthritis (RA), EVs have been isolated from synovial fluid and shown to play pathogenic roles contributing to progression of both diseases. By contrast, EVs may have therapeutic effect via the delivery of molecules that may stop disease evolution. In particular, EVs derived from mesenchymal stem cells (MSCs) reproduce the main functions of the parental cells and therefore represent the ideal type of EVs for modulating the course of either disease. The aim of this review is to discuss the role of EVs in OA and RA focusing on their potential pathogenic effect and possible therapeutic options. Special attention is given to MSCs and MSC-derived EVs for modulating OA and RA progression with the perspective of developing innovative therapeutic strategies. View Full-Text
Keywords: osteoarthritis; rheumatoid arthritis; extracellular vesicle; exosome; microparticle; mesenchymal stem cell; cell therapy osteoarthritis; rheumatoid arthritis; extracellular vesicle; exosome; microparticle; mesenchymal stem cell; cell therapy
MDPI and ACS Style

Cosenza, S.; Ruiz, M.; Maumus, M.; Jorgensen, C.; Noël, D. Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles. Int. J. Mol. Sci. 2017, 18, 889. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040889

AMA Style

Cosenza S, Ruiz M, Maumus M, Jorgensen C, Noël D. Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles. International Journal of Molecular Sciences. 2017; 18(4):889. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040889

Chicago/Turabian Style

Cosenza, Stella, Maxime Ruiz, Marie Maumus, Christian Jorgensen, and Danièle Noël. 2017. "Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles" International Journal of Molecular Sciences 18, no. 4: 889. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040889

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop